Trials in Progress Abstracts
ASCO recognizes the importance of bringing together researchers to discuss ongoing trials. The Trials in Progress abstracts provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. In addition, the Trials in Progress abstracts presented in the General Poster Session highlight the transition of emerging biologic pathways and new agents into the clinic—providing "coming attractions" for oncologists in clinical practice.
All phases of clinical research (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion in a Trials in Progress abstract submission. Trials submitted to this session are ongoing and have not reached prespecified endpoints for analysis. As such, inclusion of results would be improper and is strictly forbidden.
What is the abstract selection process for submitted Trials in Progress abstracts?
Abstracts will be reviewed by the ASCO Scientific Program Committee. Abstracts will be evaluated on the strength of the science underlying the trial, novelty of the study design and/or correlatives, potential for collaboration, and overall interest to the ASCO community.
What is acceptable in a Trials in Progress abstract and poster?
- Scientific background/rationale for the trial. Preclinical and/or earlier-phase clinical data that has already been publically presented or published may be included with references. The Trials in Progress session should not be used to present preclinical or earlier-phase clinical data for the first time.
|
- Trial design and statistical methods, highlighting any novel aspects of the design
|
- Treatment or intervention planned
|
- Major eligibility criteria, highlighting unusual aspects
|
- Correlative studies of particular interest
|
- Current enrollment without providing results or endpoints
|
| |
- Enrollment must have already begun or have been completed with no data analysis available.
|
- Phase I studies may say, “Cohorts 1 and 2 have been completed without DLT. Enrollment to cohort 3 began in January 2011.”
|
- Phase II studies may report, “8 of planned 32 patients have been enrolled” or “Prespecified activity goal for the first stage of accrual was met; second stage accrual began in January 2011.”
|
- Phase III trials may report, “The DMC last reviewed the trial in December 2010 and suggested that the trial continue as planned.”
|
- Clinical trial registry number (required)
|
What is not acceptable in a Trials in Progress abstract?